SCHEMBL10057673

SCHEMBL10057673

CC(C)N1CCC(c2cccc(Cl)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN2 Q8IZK6 1/20 0.55
KCNH2 Q12809 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
DRD2 P14416 2/20 0.46
DRD3 P35462 2/20 0.46
DRD4 P21917 1/20 0.46
GRM2 Q14416 1/20 0.46
ADAM17 P78536 1/20 0.46
ADAMTS5 Q9UNA0 1/20 0.46
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
HSD11B1 P28845 1/20 0.43
PDE9A O76083 1/20 0.42
F10 P00742 2/20 0.42
CCR5 P51681 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10057676 0.83 PARP1 (0.43) MCOLN2KCNH2HRH3DRD2GRM2
SCHEMBL20842176 0.82 HTR2C (0.56) KCNH2HRH3DRD2DRD3DRD4
SCHEMBL10078845 0.81 QDPR (0.53) DRD2DRD3DRD4GRM2MAPK11
SCHEMBL23102155 0.81 MCOLN2 (0.42) MCOLN2KCNH2HRH3DRD2DRD3
SCHEMBL2389123 0.81 DRD2 (0.60) KCNH2HRH3DRD2DRD3DRD4
SCHEMBL21026945 0.81 KCNH2 (0.48) MCOLN2KCNH2HRH3DRD2DRD3
SCHEMBL10057652 0.81 VCP (0.50) MCOLN2KCNH2HRH3DRD2DRD3
SCHEMBL10265025 0.80 DRD2 (0.47) MCOLN2DRD2DRD3DRD4GRM2
SCHEMBL10057671 0.80 DRD2 (0.57) KCNH2HRH3DRD2
SCHEMBL2603282 0.79 HRH3 (0.69) KCNH2HRH3DRD2CCR5KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed
US-8148404-B2 Modulators of CB1 receptors 7TM PHARMA A/S (DK) 2012-04-03 US disclosed
US-20100144701-A1 Modulators of CB1 Receptors 7TM PHARMA A/S (DK) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G MCOLN2 2872/4885KCNH2 4523/4885HRH3 4735/4885
US-20100144701-A1 Modulators of CB1 Receptors CNR1, CNR2, GPR6 MCOLN2 2272/4885KCNH2 1148/4885HRH3 127/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MCOLN2 2869/4885KCNH2 4564/4885HRH3 4702/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MCOLN2 2869/4885KCNH2 4564/4885HRH3 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.